This company has been marked as potentially delisted and may not be actively trading. NYSE:ENFN Enfusion (ENFN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Enfusion Stock (NYSE:ENFN) 30 days 90 days 365 days Advanced Chart Get Enfusion alerts:Sign Up Key Stats Today's Range$10.74▼$10.8750-Day Range$10.85▼$10.8552-Week Range$7.83▼$11.80Volume2.46 million shsAverage Volume735,304 shsMarket Capitalization$1.40 billionP/E Ratio271.29Dividend YieldN/APrice Target$12.25Consensus RatingHold Company Overview Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois. Read More Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Email Address ENFN Stock News HeadlinesClearwater Analytics reinstated with an Overweight at JPMorganApril 26, 2025 | markets.businessinsider.comClearwater Analytics: 3 Acquisitions That Make This A Strong BuyApril 24, 2025 | seekingalpha.comCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. July 24 at 2:00 AM | Timothy Sykes (Ad)Clearwater Analytics Finalizes Acquisition of EnfusionApril 21, 2025 | businesswire.comClearwater Analytics and Enfusion Announce Election Deadline for Enfusion Shareholders to Elect Form of Merger ConsiderationApril 2, 2025 | businesswire.comENFUSION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enfusion, Inc. - ENFNApril 2, 2025 | businesswire.comEnfusion, Inc.: Enfusion Announces Fourth Quarter and Full Year 2024 ResultsMarch 4, 2025 | finanznachrichten.deEnfusion Announces Fourth Quarter and Full Year 2024 ResultsMarch 3, 2025 | businesswire.comSee More Headlines ENFN Stock Analysis - Frequently Asked Questions How were Enfusion's earnings last quarter? Enfusion, Inc. (NYSE:ENFN) released its quarterly earnings data on Monday, March, 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by $0.02. The company had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. Enfusion had a net margin of 1.70% and a trailing twelve-month return on equity of 6.67%. When did Enfusion IPO? Enfusion (ENFN) raised $300 million in an IPO on Thursday, October 21st 2021. The company issued 18,750,000 shares at $15.00-$17.00 per share. What other stocks do shareholders of Enfusion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enfusion investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings3/03/2025Today7/24/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorComputer and Technology Industry Prepackaged software Sub-IndustryComputer Software Current SymbolNYSE:ENFN CIK1868912 Webwww.enfusion.com Phone312-253-9800FaxN/AEmployees890Year FoundedN/APrice Target and Rating Average Price Target for Enfusion$12.25 High Price Target$13.00 Low Price Target$11.50 Potential Upside/Downside+12.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$0.03 Trailing P/E Ratio271.29 Forward P/E Ratio180.82 P/E Growth1.85Net Income$6.03 million Net Margins1.70% Pretax Margin3.64% Return on Equity6.67% Return on Assets4.86% Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.62 Sales & Book Value Annual Sales$201.61 million Price / Sales6.94 Cash Flow$0.14 per share Price / Cash Flow78.75 Book Value$0.61 per share Price / Book17.79Miscellaneous Outstanding Shares129,001,000Free Float81,720,000Market Cap$1.40 billion OptionableOptionable Beta0.92 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NYSE:ENFN) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enfusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enfusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.